<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="//brt-medaff-stage.workhorsewebit.com/wp-content/plugins/wordpress-seo/css/main-sitemap.xsl"?>
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-image/1.1 http://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resources/</loc>
		<lastmod>2026-07-09T15:02:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/non-motor-effects-of-bemdaneprocel-for-parkinsons-disease-results-up-to-18-months-from-a-phase-1-study/</loc>
		<lastmod>2026-07-09T14:54:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/safety-tolerability-and-clinical-assessment-of-bemdaneprocel-for-parkinsons-disease-results-up-to-18-months-from-a-phase-1-study/</loc>
		<lastmod>2026-07-09T14:55:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/continued-evaluation-of-safety-motor-and-non-motor-outcomes-in-participants-with-parkinsons-disease-through-3-years-after-bemdaneprocel-administration/</loc>
		<lastmod>2026-07-09T14:56:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/motor-and-non-motor-outcomes-of-bemdaneprocel-in-people-with-parkinsons-disease-results-up-to-24-months-from-a-phase-1-study/</loc>
		<lastmod>2026-07-09T14:56:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/continued-evaluation-of-bemdaneprocel-following-a-phase-1-study-for-parkinsons-disease-outcomes-through-3-years/</loc>
		<lastmod>2026-07-09T14:57:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/safety-and-tolerability-of-bemdaneprocel-in-people-with-parkinsons-disease-results-up-to-24-months-from-a-phase-1-study-4/</loc>
		<lastmod>2026-07-09T14:58:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/expdite-2-a-phase-3-randomized-sham-controlled-double-blind-trial-to-evaluate-bemdaneprocel-3/</loc>
		<lastmod>2026-07-09T14:58:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/imaging-outcomes-of-a-dopaminergic-neuronal-cell-therapy-for-parkinsons-disease-18-month-results/</loc>
		<lastmod>2026-07-09T14:59:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/phase-i-trial-of-hes-cell-derived-dopaminergic-neurons-for-parkinsons-disease/</loc>
		<lastmod>2026-07-09T15:01:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://brt-medaff-stage.workhorsewebit.com/resource/dopaminergic-neuronal-cell-therapy-for-parkinsons-disease-results-from-a-phase-1-study-of-bemdaneprocel/</loc>
		<lastmod>2026-07-09T15:02:46+00:00</lastmod>
	</url>
</urlset>
<!-- XML Sitemap generated by Yoast SEO -->